Oppenheimer Lowers OnKure Therapeutics (NASDAQ:OKUR) Price Target to $30.00

OnKure Therapeutics (NASDAQ:OKUR) had its target price trimmed by Oppenheimer from $35.00 to $30.00 in a research note released on Tuesday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other equities research analysts have also recently weighed in on OKUR. Leerink Partnrs upgraded OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Leerink Partners assumed coverage on OnKure Therapeutics in a research note on Thursday, December 5th. They issued an “outperform” rating and a $33.00 price objective for the company. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, OnKure Therapeutics has an average rating of “Buy” and a consensus target price of $34.33.

OnKure Therapeutics Stock Performance

Shares of NASDAQ OKUR opened at $4.95 on Tuesday. OnKure Therapeutics has a twelve month low of $4.57 and a twelve month high of $20.00. The company has a 50 day moving average price of $5.97. The stock has a market capitalization of $16.55 million, a PE ratio of -0.41 and a beta of 0.28.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings data on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.51). Equities analysts predict that OnKure Therapeutics will post -4.05 EPS for the current year.

Institutional Investors Weigh In On OnKure Therapeutics

Several large investors have recently modified their holdings of OKUR. Barclays PLC purchased a new stake in shares of OnKure Therapeutics during the fourth quarter worth approximately $75,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of OnKure Therapeutics during the fourth quarter worth approximately $104,000. Walleye Capital LLC purchased a new stake in shares of OnKure Therapeutics during the fourth quarter worth approximately $116,000. Two Sigma Advisers LP purchased a new stake in shares of OnKure Therapeutics during the fourth quarter worth approximately $122,000. Finally, Shay Capital LLC acquired a new position in OnKure Therapeutics during the fourth quarter worth $129,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.